by Dr. Yashashwini Reddy | Sep 10, 2025
🔴 Critical Mistakes in Root Cause Investigation (RCI): Jumping to Conclusions – Assuming the cause without evidence or proper investigation. Superficial Investigation – Stopping at symptoms instead of identifying the true underlying cause. Poor Documentation –...
by Dr. Yashashwini Reddy | Sep 9, 2025
✅ Areas to Inspect During Self-Inspection in Pharmaceuticals Personnel & Training Verify staff qualifications, training records, and adherence to GMP practices. Premises & Facilities Check cleanliness, maintenance, pest control, HVAC systems, and environmental...
by Dr. Yashashwini Reddy | Sep 9, 2025
🔑 Tips for Effective Internal Audit System Establish Clear Objectives Define the purpose of the audit (compliance, efficiency, risk identification, or process improvement). Develop a Comprehensive Audit Plan Prepare a risk-based annual audit schedule covering all...
by Dr. Yashashwini Reddy | Sep 8, 2025
Recent GMP Violations at Indian Pharma Facilities 1. Granules India (Telangana) In a 2024 inspection, the FDA observed severe cross-contamination issues: residues in air ducts, microbial contamination despite HEPA filters, bird droppings and feathers in production...
by Dr. Yashashwini Reddy | Sep 8, 2025
Difference Between FDA Form 483 and Warning Letter 1. FDA Form 483 (Inspectional Observations) Issued when: FDA inspectors observe potential violations of the Food, Drug, and Cosmetic Act (FD&C Act) during an inspection. Purpose: To notify company management of...
